Cargando…
PCR138 Association of SARS-CoV-2 Omicron Ba.1 on Adherence to Oral Tetrabenazine Congener and Quality of Life of Patients Diagnosed With Huntington's Disease With Chorea or Tardive Dyskinesia on the Service of a USA Specialty Pharmacy
Autores principales: | Burruss, R, Alhabashi, R, Arikian, V |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747498/ http://dx.doi.org/10.1016/j.jval.2022.09.2073 |
Ejemplares similares
-
Treatment of Tardive Dyskinesia by tetrabenazine, clonazepam and vitamin E
por: Sharma, Himanshu
Publicado: (2009) -
Tardive Dyskinesia After Aripiprazole Treatment That Improved With Tetrabenazine, Clozapine, and Botulinum Toxin
por: Aguilar, Lourdes, et al.
Publicado: (2019) -
Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease
por: Frank, Samuel
Publicado: (2010) -
Correction:Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study
por: Frank, Samuel
Publicado: (2011) -
Tetrabenazine in the treatment of Huntington’s disease
por: Paleacu, Diana
Publicado: (2007)